ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) and IM Cannabis (NASDAQ:IMCC – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, valuation, earnings, risk and dividends.
Risk and Volatility
ANI Pharmaceuticals has a beta of 0.45, suggesting that its stock price is 55% less volatile than the S&P 500. Comparatively, IM Cannabis has a beta of 2.1, suggesting that its stock price is 110% more volatile than the S&P 500.
Earnings & Valuation
This table compares ANI Pharmaceuticals and IM Cannabis”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ANI Pharmaceuticals | $883.37 million | 1.83 | $78.34 million | $4.64 | 15.13 |
| IM Cannabis | $39.17 million | 0.01 | -$8.10 million | ($60.66) | -0.03 |
ANI Pharmaceuticals has higher revenue and earnings than IM Cannabis. IM Cannabis is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares ANI Pharmaceuticals and IM Cannabis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ANI Pharmaceuticals | 11.07% | 27.37% | 10.47% |
| IM Cannabis | -39.62% | -585.96% | -58.32% |
Institutional and Insider Ownership
76.0% of ANI Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.7% of IM Cannabis shares are owned by institutional investors. 8.1% of ANI Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Analyst Recommendations
This is a summary of current ratings and price targets for ANI Pharmaceuticals and IM Cannabis, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ANI Pharmaceuticals | 0 | 4 | 5 | 0 | 2.56 |
| IM Cannabis | 1 | 0 | 0 | 0 | 1.00 |
ANI Pharmaceuticals currently has a consensus price target of $105.57, indicating a potential upside of 50.41%. Given ANI Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe ANI Pharmaceuticals is more favorable than IM Cannabis.
Summary
ANI Pharmaceuticals beats IM Cannabis on 13 of the 14 factors compared between the two stocks.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
About IM Cannabis
IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
